ArticleScientific reports2025
Impact of citrate dialysate on middle molecular weight uremic toxin adsorption and removal in high-flux and MCO dialysis membranes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hemodialysis treatment with bicarbonate requires a weak acid to prevent salt precipitation. Acetate is implemented in chronic hemodialysis while citrate is used in continuous treatments due to its anticoagulation properties, offering a plethora of clinical benefits and reduces protein adsorption to polysulfone membranes. The outcomes of citrate in the adsorption properties of hemodialyzers, especially on medium cut-off hemodialyzers are unknown. To check 21 chronic hemodialysis patients underwent their mid-weekly treatment using a FX CorDiax 80, Solacea-19 H or a Theranova 400 hemodialyzer combined with acetate or citrate-based dialysate. Pre and post-treatment blood samples were taken to calculate the reduction ratio of several uremic surrogates and proteins. An elution protocol was performed to every hemodialyzer to assess adsorption. Significant removal differences among membranes were found for β2-microglobulin, TNF-α, κ and λ free light chains, as hemodiafiltration and expanded hemodialysis were compared regarding the acidifier. Citrate significantly (p = 0.011) improved removal for κ free light chains (for Theranova 400) whilst all other solutes showed no significant different depuration between acidifiers. For each membrane type analyzed, no statistical differences in adsorption were found between concentrates on the same membrane. Implementing the citrate-based concentrate does not modify removal and adsorption properties of high-flux and medium cut-off membranes. The clinical benefit shown in other studies of using citrate instead of acetate could not be explained because of this mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.